Comparison of the effects of pramipexole and gabapentin on the treatment of restless leg syndrome in end-stage chronic renal failure patients undergoing hemodialysis

Hajian, Sepideh; Nikfam, Mohammad Reza Rajabpoor; Esmayeilzad, Zahra

doi:10.34172/jnp.2020.25

Cited by 3 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The basic characteristics of the included literature are shown in Table 2. One of the articles is a four‐arm test, 33 two articles are a three‐arm test, 34,35 and six articles are a two‐arm test 21,36–40 . Nine studies included in this article are randomized controlled trials, and one study is an open randomized crossover trial.…”

Section: Resultsmentioning

confidence: 99%

“…There are nine interventions involved including vitamin C ( n = 30), vitamin E ( n = 15), vitamin C + vitamin E ( n = 15), pramipexole ( n = 44), ropinirole ( n = 17), gabapentin ( n = 72), levodopa‐C ( n = 50), rotigotine ( n = 15), and iron ( n = 27). The main indicators analyzed in this article are IRLS, 33–39 IRLS‐6, 40 and RLS‐3 21 . The specific problems and scores of IRLS, IRLS‐6, and RLS‐3 are shown in Table 3.…”

Section: Resultsmentioning

confidence: 99%

“…37 One of the exclusion criteria for the two studies was iron deficiency. 36,38 The inclusion criteria of five articles did not mention the issue of iron. 21,[33][34][35]40 This is a main bias in the study.…”

Section: Discussionmentioning

confidence: 99%

“…One of the articles is a four-arm test, 33 two articles are a three-arm test, 34,35 and six articles are a two-arm test. 21,[36][37][38][39][40] The main indicators analyzed in this article are IRLS, [33][34][35][36][37][38][39] IRLS-6, 40 and RLS-3. 21 The specific problems and scores of IRLS, IRLS-6, and RLS-3 are shown in Table 3.…”

Section: Features Of the Included Literaturementioning

confidence: 99%

“…T A B L E 4Hajian et al, 202038 NoDeng et al, 201739 No Pellecchia et al, 200440 Levodopa: 1 patient developed severe vomiting, leading to the discontinuation of the studySloand et al, 2004 21 Iron: 10, with different symptoms; Placebo: 8, with different symptoms…”

mentioning

confidence: 99%

See 4 more Smart Citations

A network meta‐analysis of the effectiveness and safety of drugs for restless legs syndrome in dialysis patients

Tang

Sun

et al. 2021

Seminars in Dialysis

View full text Add to dashboard Cite

Objective: To evaluate the efficacy and safety of nine pharmacological interventions for restless legs syndrome (RLS) in dialysis patients. Methods: An electronic database was used to retrieve eligible trials from PubMed, Cochrane, Embase, and Web of Science. Stata 14.2 software was used to perform network meta‐analysis. The primary measure was the RLS score, and the secondary measure was used to evaluate the side effects of the drug. The surface under the cumulative ranking curve method was used to rank the merits of intervention measures. A comparison of the two interventions is shown on a league table. Results: Finally, nine randomized controlled trials (RCTs) with a total of 377 participants were included. From the results of the network meta‐analysis, all treatments ranked higher than placebo in terms of improving clinical symptoms, but only vitamin C (standardized mean difference [SMD] = −1.47 95% confidence interval [CI] −2.89, −0.05) showed significant differences compared with placebo. In terms of safety, there were no serious adverse reactions to any of the treatments compared to placebo. Conclusion: Currently, existing evidence suggests that vitamin C may be the most ideal drug to improve the symptoms of RLS in dialysis patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Features Of the Included Literaturementioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

A network meta‐analysis of the effectiveness and safety of drugs for restless legs syndrome in dialysis patients

Tang

Sun

et al. 2021

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

Pharmacological and non-pharmacological treatments for restless legs syndrome in end-stage kidney disease: a systematic review and component network meta-analysis

Chen

Lee

et al. 2021

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Background Restless legs syndrome (RLS) is common among patients with end stage kidney disease (ESKD) and is associated with poor outcomes. Several recently published studies had focused on pharmacological and nonpharmacological treatments of RLS, but an updated meta-analysis has not been conducted. Methods The study population was adult ESKD patients on dialysis with RLS. Randomized controlled trials were selected. The primary outcome was reduction in RLS severity. The secondary outcomes were improvement in sleep quality and treatment-related adverse events. Frequentist standard network meta-analysis and additive component network meta-analysis was performed. The evidence certainty was assessed using Confidence in NMA (CINeMA) framework. Results A total of 24 RCTs with 1,252 participants were enrolled and 14 interventions were compared. Cool dialysate produced the largest RLS severity score reduction (MD: 16.82, 95% CI: 10.635–23.02) and high level of confidence. Other potential non-pharmacologic interventions including intradialytic stretching exercise (MD: 12.00, 95% CI: 7.04–16.97) and aromatherapy massage (MD: 10.91, 95% CI: 6.96–14.85) but all with limited confidence of evidence. Among the pharmacological interventions, gabapentin was the most effective (MD: 8.95, 95% CI: 1.95–15.85), which also improved sleep quality (SMD: 2.00, 95% CI: 0.47–3.53). No statically significant adverse events were detected. Conclusions The NMA supports that cool dialysate is appropriate to apply to treat patients with ESKD and RLS. Gabapentin is most effective pharmacologic intervention which also might improve sleep quality. Further parallel RCTs with sufficient sample sizes are required to evaluate these potential interventions and long-term effects.

show abstract

Comparison the effect of valerian and gabapentin on RLS and sleep quality in hemodialysis patients: A randomized clinical trial

et al. 2023

View full text Add to dashboard Cite

Introduction: This study aimed to compare the effect of valerian and gabapentin on restless legs syndrome (RLS) and sleep quality in HD patients. Methods: In this cross over clinical trial study, 40 HD patients allocated into a valerian and gabapentin group. In the first phase of the study, Group A received valerian and Group B received gabapentin 1 h before bedtime for 1 month. In the second phase, the two groups' treatment regimen was swapped. After a 1-month washout period, the same process was repeated on the crossover groups.Results: After the first phase, the mean score of RLS was lower in the gabapentin group. But there was no statistically significant difference between the two groups in terms of sleep quality score before and after the first and second interventions. Conclusion: Gabapentin is more effective than valerian in improving RLS, but both are equally effective in improving sleep quality.

show abstract

Comparison of the effects of pramipexole and gabapentin on the treatment of restless leg syndrome in end-stage chronic renal failure patients undergoing hemodialysis

Cited by 3 publications

References 11 publications

A network meta‐analysis of the effectiveness and safety of drugs for restless legs syndrome in dialysis patients

A network meta‐analysis of the effectiveness and safety of drugs for restless legs syndrome in dialysis patients

Pharmacological and non-pharmacological treatments for restless legs syndrome in end-stage kidney disease: a systematic review and component network meta-analysis

Comparison the effect of valerian and gabapentin on RLS and sleep quality in hemodialysis patients: A randomized clinical trial

Contact Info

Product

Resources

About